CDx for NSCLC The VENTANA PD-L1 (SP263) assay is now FDA approved to detect PD-L1 across NSCLC to identify patients eligible for multiple targeted therapies.

For additional information please click video below

Please fill out the form below to have the interpretation Guide emailed to you

This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information which may not comply with any valid legal process, regulation, registration or usage in the country of your origin. © 2023 Roche Diagnostics